

1 **Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP,**
2 **and a rapid antigen test to diagnose COVID-19**

3

4 Mayu Ikeda^{a†}, Kazuo Imai^{ab†*}, Sakiko Tabata^a, Kazuyasu Miyoshi^a, Nami Murahara^a, Tsukasa
5 Mizuno^a, Midori Horiuchi^a, Kento Kato^a, Yoshitaka Imoto^a, Maki Iwata^a, Satoshi Mimura^a,
6 Toshimitsu Ito^a, Kaku Tamura^a, Yasuyuki Kato^c

7 †Both authors contributed equally to this manuscript.

8

9 ^aSelf-Defense Forces Central Hospital, Tokyo, Japan

10 ^bDepartment of Infectious Disease and Infection Control, Saitama Medical University,
11 Saitama, Japan

12 ^cDepartment of Infectious Diseases, International University of Health and Welfare Narita
13 Hospital, Chiba, Japan

14

15 ***Corresponding author:**

16 Kazuo Imai, M.D.

17 Self-Defense Forces Central Hospital, 24-2-1 Ikejiri, Setagaya-ku, Tokyo, 154-0001, Japan

18 E-mail: k_imai@saitama-med.ac.jp

19 Tel: +81-3-3411-0151

20

21 **Alternate corresponding author:**

22 Kazuyasu Miyoshi, M.D.

23 Self-Defense Forces Central Hospital, 24-2-1 Ikejiri, Setagaya-ku, Tokyo, 154-0001, Japan

24 E-mail: kazuyasu344@gmail.com

25 Tel: +81-3-3411-0151

26 **Key words;** SARS-CoV-2, Saliva, RT-qPCR, RT-LAMP, antigen test

27

28 **Running title:** Diagnosing COVID-19 using saliva

29

30 **Key points:** Six molecular diagnostic tests showed equivalent and sufficient sensitivity in

31 clinical use in diagnosing COVID-19 in self-collected saliva samples. However, a rapid

32 SARS-CoV-2 antigen test alone is not recommended for use without further study.

33

34 **Abstract**

35 **Background:** The clinical performance of six molecular diagnostic tests and a rapid antigen

36 test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were clinically

37 evaluated for the diagnosis of coronavirus disease 2019 (COVID-19) in self-collected saliva.

38 **Methods:** Saliva samples from 103 patients with laboratory-confirmed COVID-19 (15

39 asymptomatic and 88 symptomatic) were collected on the day of hospital admission.

40 SARS-CoV-2 RNA in saliva was detected using a quantitative reverse-transcription

41 polymerase chain reaction (RT-qPCR) laboratory-developed test (LDT), a cobas

42 SARS-CoV-2 high-throughput system, three direct RT-qPCR kits, and reverse-transcription

43 loop mediated isothermal amplification (RT-LAMP). Viral antigen was detected by a rapid

44 antigen immunochromatographic assay.

45 **Results:** Of the 103 samples, viral RNA was detected in 50.5–81.6% of the specimens by

46 molecular diagnostic tests and an antigen was detected in 11.7% of the specimens by the

47 rapid antigen test. Viral RNA was detected at a significantly higher percentage (65.6–93.4%)

48 in specimens collected within 9 d of symptom onset compared to that of specimens collected

49 after at least 10 d of symptom onset (22.2–66.7%) and that of asymptomatic patients

50 (40.0–66.7%). Viral RNA was more frequently detected in saliva from males than females.

51 **Conclusions:** Self-collected saliva is an alternative specimen diagnosing COVID-19. LDT
52 RT-qPCR, cobas SARS-CoV-2 high-throughput system, direct RT-qPCR except for one
53 commercial kit, and RT-LAMP showed sufficient sensitivity in clinical use to be selectively
54 used according to clinical settings and facilities. The rapid antigen test alone is not
55 recommended for initial COVID-19 diagnosis because of its low sensitivity.
56

57 **Introduction**

58 Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory
59 syndrome coronavirus 2 (SARS-CoV-2), was first reported in 2019, in Wuhan, China, and the
60 World Health Organization subsequently declared it a pandemic [1, 2]. The large number of
61 patients with COVID-19 during outbreaks is overwhelming the capacity of national health
62 care systems; therefore, the quick and accurate identification of patients requiring supportive
63 therapies and isolation is important for the management of COVID-19.

64 The quantitative reverse-transcription polymerase chain reaction (RT-qPCR) assay for
65 SARS-CoV-2 using upper and lower respiratory tract specimens (nasopharyngeal swab,
66 throat swab, and sputum) is the gold standard for diagnosing COVID-19 [3]. Laboratory
67 developed tests (LDT) including RT-qPCR, a high-throughput RT-qPCR system (fully
68 automated from RNA extraction to reporting of results without the need for highly skilled
69 laboratory technicians), and direct rapid RNA extraction-free RT-qPCR kits (using a modified
70 RT-qPCR master mix), have been widely used worldwide [4]. Other molecular diagnostic
71 methods such as reverse-transcription loop mediated isothermal amplification (RT-LAMP)
72 have also been reported as useful for diagnosing COVID-19 in point-of care testing [5, 6].
73 Recently, a SARS-CoV-2 rapid antigen test (RAT) (ESPLINE® SARS-CoV-2; Fuji Rebio
74 Inc., Tokyo, Japan), which combines immunochromatography with an enzyme immunoassay
75 to detect the viral nucleocapsid protein, has been approved by the Japanese government [7].

76 The RAT is beginning to be used for diagnosing COVID-19 in clinical settings because it
77 does not require special equipment, it does not have a time-consuming protocol, and highly
78 skilled laboratory technicians are not essential. Although these diagnostic tests are useful in
79 the identification of patients with COVID-19, the process of collecting upper and lower
80 respiratory tract specimens increases the risk of exposure to viral droplets and there is a
81 patient burden [8]. Therefore, an alternative specimen, which can be self-collected, to
82 diagnose COVID-19 is desirable for the clinical management of COVID-19 during this
83 pandemic era [8].

84 The sensitivity of RT-qPCR on upper respiratory specimens has been reported lower
85 (32% for pharyngeal swab, and 63% for nasopharyngeal swabs) than lower respiratory
86 specimens (72% for sputum, and 93% for bronchoalveolar lavage fluid) [9]. Recently, several
87 reports highlighted the clinical usefulness of RT-qPCR analysis of saliva specimens [10-15].
88 Saliva specimens can be easily collected by the patients themselves by spitting into a
89 collection tube; thus, using saliva specimens can reduce the burden on a patient, reduce the
90 risk of exposure to viral droplets for medical workers, and reduce the time and cost of the
91 testing procedure [16]. However, the clinical usefulness of saliva specimens for diagnosing
92 COVID-19 remains controversial because the diagnostic sensitivity also vary widely between
93 69.2 and 100% for COVID-19, and it has yet to be thoroughly evaluated due to the small
94 sample size and lack of detailed clinical information [10-15, 17].

95 Here, we describe the clinical performance of various molecular diagnostic methods
96 including LDT RT-qPCR, cobas SARS-CoV-2 high-throughput system, 3 direct RT-qPCR
97 kits and RT-LAMP, and a commercial SARS-CoV-2 RAT on self-collected saliva specimens
98 in diagnosing COVID-19.

99

100 **Materials and methods**

101 *Patients and sample collection*

102 Patients with COVID-19 were enrolled in this study after being referred to the
103 Self-Defense Forces Central Hospital in Japan for isolation and treatment under the Infectious
104 Disease Control Law in effect from Feb 11 to May 13, 2020. All patients were examined for
105 the SARS-CoV-2 virus by RT-qPCR using pharyngeal and nasopharyngeal swabs collected at
106 public health institutes or hospitals in accordance with the nationally recommended method
107 in Japan [18]. On the day of admission, saliva specimens (~500 μ L) were self-collected by all
108 patients by spitting into a sterile tube. All samples were stored at -80 °C until sample
109 preparation. All sample preparation and sample analysis were conducted by SRL, Inc. (Tokyo,
110 Japan).

111 *Sample preparation*

112 Saliva specimens were diluted with phosphate-buffered saline at a volume 1–5 times in
113 accordance with the consistency and mixed with a vortex mixer. The suspension was

114 centrifuged at $20,000 \times g$ for 30 min at 4 °C and the supernatant was used in the following
115 molecular diagnostic and RAT.

116 ***Detection of viral RNA by LDT RT-qPCR using the standard protocol***

117 LDT RT-qPCR was performed according to the National Institution Infections Diseases
118 (NIID) protocol which is nationally recommended for SARS-CoV-2 detection in Japan [18].

119 Viral RNA was extracted from 140 μ L saliva specimens using a QIASymphony™ RNA Kit
120 (QIAGEN, Hilden, Germany) following the manufacturer's instructions. RT-qPCR

121 amplification of the SARS-CoV-2 nucleocapsid (N) protein gene was performed using the

122 QuantiTect®Probe RT-PCR Kit (QIAGEN) with the following sets of primers and probe. N-1

123 set: forward primer 5' –CAC ATT GGC ACC CGC AAT C - 3', reverse primer 5' – GAG

124 GAA CGA GAA GAG GCT TG - 3', probe 5' - FAM – ACT TCC TCA AGG AAC AAC ATT

125 GCC A - TAMRA- 3' [19]. N-2 set: forward primer 5' - AAA TTT TGG GGA CCA GGA AC

126 - 3', reverse primer 5' - TGG CAG CTG TGT AGG TCA AC - 3', probe 5' - FAM - ATG TCG

127 CGC ATT GGC ATG GA - TAMRA- 3' [18]. A positive result with either or both of the

128 primer and probe sets indicated the presence of viral RNA.

129 ***Detection of viral RNA by direct RT-qPCR method without RNA extraction***

130 Direct RT-qPCR methods without RNA extraction were performed using three

131 commercial kits: Method A, SARS-CoV-2 Direct Detection RT-qPCR Kit (Takara Bio Inc.

132 Kusatsu, Japan); Method B, Ampdirect™ 2019 Novel Coronavirus Detection Kit (Shimadzu

133 Corporation, Kyoto, Japan); and Method C, SARS-CoV-2 Detection Kit (Toyobo, Osaka,
134 Japan) according to the manufacturers' instructions. The kits B and C were used with the
135 same primer sets as used in the LDT RT-qPCR method. The kit A was used with the primer
136 sets recommended by Centers for Disease Control and Prevention (CDC) [20]. Processed
137 saliva specimens were directly added to the RT-qPCR master mix and then to thermal cycling,
138 directly. Methods A and C are quantitative, whereas method B is qualitative.

139 ***Detection of viral RNA by automated RT-qPCR device***

140 The cobas SARS-CoV-2 test (Roche, Basel, Switzerland) [7, 21] was performed on the
141 RT-qPCR automated cobas 8800 system (Roche) [4]. Specimens (600 µL) were loaded onto
142 the cobas 8800 with cobas SARS-CoV-2 master mix containing an internal RNA control,
143 primers, and probes targeting the specific SARS-CoV-2 open reading frame (ORF) 1 gene
144 (target 1) and envelope (E) gene (target 2). A cobas 8800 positive result for the presence of
145 SARS-CoV-2 RNA was defined as “detected” if targets 1 and 2 were detected or
146 “presumptive positive” if target 1 was not detected but target 2 was detected.

147 ***Detection of viral RNA by RT-LAMP***

148 RT-LAMP detection of SARS-CoV-2 was performed using a Loopamp®
149 2019-SARS-CoV-2 Detection Reagent Kit (Eiken Chemical, Tokyo, Japan) according to the
150 manufacturer's instructions. The reaction was conducted at 62.5 °C for 35 min with the
151 turbidity measuring real-time device LoopampEXIA® (Eiken Chemical).

152 ***Detection of SARS-CoV-2 viral antigen by rapid antigen test***

153 RAT was performed using ESPLINE® SARS-CoV-2 (Fuji Rebio Inc) according to the
154 manufacturer's instructions. In brief, the sample for analysis was obtained by dipping a swab
155 which was provided by a RAT kit into the saliva specimen and then into the sample
156 preparation mixture provided by the kit. The mixture (200 µL) was added to the sample port
157 of the antigen assay. Subsequently, 2 drops of buffer were added and the results were
158 interpreted after a 30 min incubation.

159 ***Definitions***

160 The saliva sample collection day was defined as day 1. Symptomatic cases were
161 subdivided into two groups [22]. Severe symptomatic cases were defined as patients showing
162 clinical symptoms of pneumonia (dyspnea, tachypnea, saturation of percutaneous oxygen
163 [SpO₂] < 93%, and the need for oxygen therapy). Other symptomatic cases were classified as
164 mild cases.

165 ***Ethical statement***

166 Written informed consent was obtained from each enrolled patient at the Self-Defense
167 Forces Central Hospital. This study was reviewed and approved by the Self-Defense Forces
168 Central Hospital (approval number 02-024) and International University of Health and
169 Welfare (20-Im-002-2).

170 ***Statistical analysis***

171 Continuous variables with a normal distribution were expressed as mean (\pm SD) and
172 with a non-normal distribution as median (IQR), and compared using the Student's t-test and
173 Wilcoxon rank-sum test for parametric and nonparametric data, respectively. Categorical
174 variables were expressed as number (%) and compared by χ^2 test or Fisher's exact test. The
175 Kruskal-Wallis test was used for nonparametric analysis with over three independent samples.
176 Linear regression analysis was used to assess the relationship between each molecular
177 diagnostic method. A two-sided p value < 0.05 was considered statistically significant. All
178 statistical analyses were calculated using R (v3.4.0; R Foundation for Statistical Computing,
179 Vienna, Austria [<http://www.R-project.org/>]).

180

181 **Results**

182 *Sensitivity of molecular diagnostic tests and antigen test*

183 In this study, 7 diagnostic tests for COVID-19 were compared across 103 saliva
184 specimens self-collected by 103 patients (Table 1). Singleton test was conducted for each
185 method. Among the molecular diagnostic tests, LDT RT-qPCR showed the highest sensitivity
186 on analyzing the 103 saliva samples. The direct RT-qPCR Method B exhibited higher
187 sensitivity than either Method A or C. Only 12 patients tested positive using the RAT.

188 The Ct values for the N-1 and N-2 primer sets for the direct RT-qPCR Method C (35.5
189 ± 2.2 and 34.8 ± 2.4 , respectively) were significantly ($p < 0.001$) greater than those for LDT

190 RT-qPCR (32.8 ± 4.1 and 30.1 ± 4.4 , respectively) (Figure 1). The mean detection time of
191 RT-LAMP was 19.1 min (SD = 4.0) (Figure 1). A significant correlation was observed
192 between RT-LAMP detection time and the Ct value of target 2 in the cobas SARS-CoV-2 test
193 ($p < 0.001$) (Figure 2A). All patients with a positive SARS-CoV-2 RAT also tested positive
194 for the six molecular diagnostic tests. The Ct value of target 2 in the cobas SARS-CoV-2 test
195 was significantly lower in saliva samples that tested positive by RAT compared to that of
196 samples that tested negative (25.4 ± 1.8 vs. 30.8 ± 2.7 , respectively; $p < 0.001$; Figure 2B).

197 *Effect of collection time on test sensitivity*

198 On the day of admission, 15 patients (14.6%) who did not display any symptoms were
199 classified as asymptomatic, whereas 88 patients (85.4%) were classified as COVID-19
200 symptomatic. Of the 88 symptomatic patients, saliva specimens were collected by 61 patients
201 (69.3%) within 9 d from symptom onset (early phase of onset) and by 27 patients (30.7%)
202 after 10 d from symptom onset (late phase of onset; Table 1). Samples from early phase, late
203 phase, and asymptomatic patients tested positive by molecular diagnostic tests 65.6–93.4%,
204 22.3–66.7%, and 40.0–66.7%, respectively. The detection of saliva viral RNA was
205 significantly higher in symptomatic patients who collected their saliva within 9 d from
206 symptom onset than in saliva samples collected after 10 d from symptom onset and in saliva
207 from asymptomatic patients ($p < 0.01$). There were no significant differences in prevalence of
208 positive results by RAT among the three groups.

209 *Effect of clinical background on the prevalence of viral RNA in saliva*

210 The baseline clinical characteristics of the 103 patients enrolled in this study are
211 presented in Table 2. Briefly, patient age ranged from 18 to 87 years (median, 46 years; IQR,
212 38–63 years), and 66 (64.1%) patients were male. The time from symptom onset to sample
213 collection was 1–14 d (median, 7 d; IQR, 6–10 d). The time from the initial RT-qPCR
214 positive test to sample collection was 1–8 d (median, 4 d; IQR, 3–5 d). Of the 88
215 symptomatic patients, 72 (81.8%) and 16 (18.2%) were classified as mild and severe
216 COVID-19, respectively.

217 The effect of clinical background against the prevalence of viral RNA in saliva was
218 analyzed using the results of LDT RT-qPCR, which had the highest sensitivity of all of the
219 methods in this study. Among 103 patients, a significant male sex bias was noted in samples
220 that tested positive for the virus compared to that of samples which tested negative (69.0% vs.
221 42.1%, respectively; $p = 0.035$) (Table 2). There were no significant differences in
222 distribution by age or disease activity between patients detected or undetected with viral RNA
223 ($p > 0.05$).

224 A summary of clinical symptoms and disease severity is shown for 88 symptomatic
225 patients in Table 3. The disease symptom cough was observed in 41 of 74 patients (55.4%)
226 with viral RNA in their saliva compared to 4 of 14 patients (28.6%) who did not test positive

227 for viral RNA ($p = 0.084$). All severe patients (16/16, 100%) tested positive for viral RNA in
228 their saliva, while 58 of 72 (78.4%) mild patients tested positive ($p = 0.064$).

229

230 **Discussion**

231 Here, we present evidence for the clinical usefulness of saliva specimens in diagnosing
232 COVID-19. Previous studies reported that the sensitivity of RT-qPCR-analyzed saliva
233 specimens initially collected from hospitalized patients was 69.2–100% for COVID-19
234 [10-15, 17]. The contradiction in sensitivity probably reflects differences in the clinical
235 background and timing of sampling in each study. Becker et al, reported the lowest sensitivity
236 (69.2%) using the clinical samples which were collected in late phase of onset [17]. On the
237 other hands, Azzi et al, reported the highest sensitivity on saliva (100%) among hospitalized
238 patients with severe and very severe disease [11]. In our study, the detection of viral RNA in
239 saliva was significantly higher in samples collected in the early phase of symptom onset
240 (within 9 d) compared to that in samples collected in the late phase of symptom onset (over
241 10 d), and in male patients versus female patients. Since the viral load of SARS-CoV-2 in
242 saliva has been shown to decline from symptom onset [12], saliva specimens should be
243 collected during the early phase of symptom onset to increase sensitivity.

244 SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) on host cells found in
245 the salivary gland and tongue tissues as well as nasal mucosa, nasopharynx, and lung tissue

246 [23, 24] as a cell receptor to invade human cells [25]. Chen et al. collected saliva directly
247 from the opening of the salivary gland and showed that SARS-CoV-2 can infect salivary
248 glands [26]. The whole saliva flow rate is known to be higher in males than in females since
249 it is associated with the size of the salivary gland [27]. The difference in saliva flow rate may
250 affect the viral load in saliva and be associated with the difference in diagnostic sensitivity
251 between males and females. We did not observe significant differences in disease severity or
252 clinical symptoms between patients detected with or without saliva viral RNA; however, the
253 prevalence of severe disease and the symptom of cough were frequently observed in patients
254 detected with viral RNA in their saliva. Regarding disease activity, the presence of viral RNA
255 was detected in more than 50% of the asymptomatic patients. These findings support
256 previous studies reporting the presence of viral RNA in saliva of both symptomatic and
257 asymptomatic patients [14]. Therefore, our findings revealed that saliva, collected in the early
258 phase of symptom onset, is a reliable and practical source for the screening and diagnosing of
259 COVID-19.

260 The clinical performance of direct RT-qPCR kits and RT-LAMP, and any correlation
261 with RT-qPCR results were not well evaluated because of the small number of clinical
262 specimens collected from patients in previous studies [5, 6, 28]. The sensitivity of RT-LAMP
263 for SARS-CoV-2 using upper and lower respiratory tract specimens has been reported as
264 equivalent to RT-qPCR [5, 6, 28]. However, our results indicate that the sensitivity of

265 RT-LAMP is inferior to LDT RT-qPCR and cobas SARS-CoV-2 test for COVID-19 in saliva
266 specimens. Direct RT-qPCR kits without an RNA extraction process can reduce the time, cost,
267 and human resources needed to conduct the assay. However, we showed that there is a large
268 difference in sensitivity among the direct RT-qPCR kits. It is necessary to pay attention to the
269 false-negative results of RT-LAMP and direct RT-qPCR kits, especially when testing saliva
270 samples. In clinical settings with limited medical and human resources, using RT-LAMP and
271 direct RT-qPCR kits are options for screening and diagnosing COVID-19 because of their
272 simplicity.

273 In comparison with molecular diagnostic tests, the SARS-CoV-2 RAT of saliva
274 specimens showed low sensitivity. The sensitivity of RAT is still unclear, not only when using
275 saliva samples but also when using nasopharyngeal swab specimens [7]. The experiment to
276 compare the sensitivity of RT-qPCR and RAT prior to the approval as in vitro diagnostic test
277 by Japanese government showed that sensitivity of RAT was 66.7% (16/24 patients) for
278 nasopharyngeal swabs; furthermore, low sensitivity specimens contained a low viral copy
279 number (50% sensitivity [6/12 patients] for specimens containing < 100 copies/test) [7]. Our
280 findings also suggest that the RAT requires a high viral copy number to get positive result.
281 This kit was not originally compatible with saliva specimens and the freeze-thaw process
282 may have affected sensitivity. Improvements in sample preparation may increase its
283 sensitivity.

284 Our study had several limitations. First, the saliva specimens were collected from
285 patients 3 d (median) after receiving their first positive RT-qPCR result from analysis of
286 upper respiratory specimens. Directly comparing the sensitivity between saliva and other
287 upper or lower respiratory specimens is difficult in our study design because the viral load in
288 the clinical specimens vary with time [13]. Second, although the high specificity of RT-qPCR
289 for SARS-CoV-2 has been confirmed [6, 18, 28-31], the specificities should be analyzed by
290 also using saliva from non-COVID-19 patients. Further studies are warranted to determine
291 the usefulness of saliva specimens for screening and diagnosing COVID-19.

292

293 **Conclusions**

294 Self-collected saliva in the early phase of symptom onset is an alternative specimen
295 diagnosing COVID-19. LDT RT-qPCR, cobas SARS-CoV2 high-throughput system, direct
296 RT-qPCR kits except for one commercial kit, and RT-LAMP showed equivalent and sufficient
297 sensitivity in clinical use and can be selectively used according to the clinical setting and
298 facilities. The rapid SARS-CoV-2 antigen test alone is not recommended for use at this time
299 due to low sensitivity.

300

301 **Conflict of interest**

302 The authors declare that they have no conflicts of interests.

303

304 **Funding**

305 This work was supported by the Health, Labour and Welfare Policy Research Grants,
306 Research on Emerging and Re-emerging Infectious Diseases and Immunization [grant
307 number 20HA2002].

308

309 **Acknowledgments**

310 We thank clinical laboratory technicians at the Self-Defense Forces Central Hospital
311 for sample collecting, and everyone involved in the COVID-19 Task Force at the
312 Self-Defense Forces Central Hospital, and members who were assembled from other
313 institutes of the Japan Self-Defense Forces.

314

315 **Authors' contributions**

316 YK and KI, study conception and design; MI and ST, collecting data and performing
317 data analysis; MI, KI, KM, KT and YK manuscript drafting and editing; NM, TM, MH, KK,
318 YI and MI, manuscript revision; SM, TI and KT, study supervision. All authors have read and
319 approved the final manuscript.

320 **References**

- 321 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
322 coronavirus in Wuhan, China. *Lancet* 2020; 395(10223): 497-506.
- 323 2. WHO. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. [Latest
324 accessed 30/May/2020]
- 325 3. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2.
326 *JAMA* 2020. DOI:10.1001/jama.2020.8259
- 327 4. Cobb B, Simon CO, Stramer SL, et al. The cobas® 6800/8800 System: a new era of
328 automation in molecular diagnostics. *Expert Rev Mol Diagn* 2017; 17(2): 167-80.
- 329 5. Yu L, Wu S, Hao X, et al. Rapid detection of COVID-19 coronavirus using a reverse
330 transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. *Clin*
331 *Chem* 2020. DOI: <https://doi.org/10.1093/clinchem/hvaa102>
- 332 6. Kitagawa Y, Orihara Y, Kawamura R, et al. Evaluation of rapid diagnosis of novel
333 coronavirus disease (COVID-19) using loop-mediated isothermal amplification. *J Clin Virol*
334 2020. DOI: <https://doi.org/10.1016/j.jcv.2020.104446>
- 335 7. Japanese Ministry of Health, Labour and Welfare. Approval of In Vitro
336 Diagnostics for the novel coronavirus infection/
337 <https://www.mhlw.go.jp/content/11124500/000632304.pdf>. [Latest accessed 30/May/2020]

- 338 8. Wehrhahn MC, Robson J, Brown S, et al. Self-collection: An appropriate alternative
339 during the SARS-CoV-2 pandemic. *J Clin Virol* 2020; 128: 104417. DOI:
340 <https://doi.org/10.1016/j.jcv.2020.104417>
- 341 9. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of
342 Clinical Specimens. *JAMA* 2020; 323(18): 1843-4.
- 343 10. Pasomsub E, Watcharananan SP, Boonyawat K, et al. Saliva sample as a
344 non-invasive specimen for the diagnosis of coronavirus disease-2019 (COVID-19): a
345 cross-sectional study. *Clin Microbiol Infect* 2020.
346 DOI:<https://doi.org/10.1016/j.cmi.2020.05.001>
- 347 11. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect
348 SARS-CoV-2. *J Infect* 2020. DOI:<https://doi.org/10.1016/j.jinf.2020.04.005>
- 349 12. To KK-W, Tsang OT-Y, Chik-Yan Yip C, et al. Consistent detection of 2019 novel
350 coronavirus in saliva. *Clin Infect Dis* 2020. DOI: <https://doi.org/10.1093/cid/ciaa149>
- 351 13. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior
352 oropharyngeal saliva samples and serum antibody responses during infection by
353 SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 2020; 20(5): 565-74.
- 354 14. Kojima N, Turner F, Slepnev V, et al. Self-Collected Oral Fluid and Nasal Swabs
355 Demonstrate Comparable Sensitivity to Clinician Collected Nasopharyngeal Swabs for
356 Covid-19 Detection. *medRxiv* 2020: 2020.04.11.20062372.

- 357 15. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for
358 SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. medRxiv 2020:
359 2020.04.16.20067835.
- 360 16. To KKW, Yip CCY, Lai CYW, et al. Saliva as a diagnostic specimen for testing
361 respiratory virus by a point-of-care molecular assay: a diagnostic validity study. Clin
362 Microbiol Infect 2019; 25(3): 372-8.
- 363 17. Becker D, Sandoval E, Amin A, et al. Saliva is less sensitive than nasopharyngeal
364 swabs for COVID-19 detection in the community setting. medRxiv 2020:
365 2020.05.11.20092338.
- 366 18. Shirato K, Nao N, Katano H, et al. Development of Genetic Diagnostic Methods for
367 Novel Coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis 2020. DOI:
368 10.7883/yoken.JJID.2020.061
- 369 19. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus
370 (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25(3): 2000045. DOI: doi:
371 10.2807/1560-7917.ES.2020.25.3.2000045
- 372 20. Centers for Disease Control and Prevention. Research Use Only 2019-Novel
373 Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes.
374 <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>. [Latest
375 accessed 30/May/2020]

- 376 21. U.S. Food and Drug Administration. cobas@SARS-CoV-2.
377 <https://www.fda.gov/media/136049/download>. [Latest accessed 30/May/2020]
- 378 22. Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage
379 strategies for 2019 novel coronavirus disease in fever clinics. *Lancet Respir Med* 2020; 8(3):
380 e11-e2.
- 381 23. Song J, Li Y, Huang X, et al. Systematic Analysis of ACE2 and TMPRSS2
382 Expression in Salivary Glands Reveals Underlying Transmission Mechanism Caused by
383 SARS-CoV-2. *J Med Virol* 2020. DOI: <https://doi.org/10.1002/jmv.26045>
- 384 24. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue
385 distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in
386 understanding SARS pathogenesis. *J Pathol* 2004; 203(2): 631-7.
- 387 25. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends
388 on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;
389 181(2): 271-80.e8.
- 390 26. Chai X, Hu L, Zhang Y, et al. Specific ACE2 Expression in Cholangiocytes May
391 Cause Liver Damage After 2019-nCoV Infection. *bioRxiv* 2020: 2020.02.03.931766.
- 392 27. Inoue H, Ono K, Masuda W, et al. Gender difference in unstimulated whole saliva
393 flow rate and salivary gland sizes. *Arch Oral Biol* 2006; 51(12): 1055-60.

- 394 28. Lieberman JA, Pepper G, Naccache SN, Huang M-L, Jerome KR, Greninger AL.
395 Comparison of Commercially Available and Laboratory Developed Assays for in vitro
396 Detection of SARS-CoV-2 in Clinical Laboratories. J Clin Microbiol 2020. DOI:
397 10.1128/JCM.00821-20
- 398 29. Pfefferle S, Reucher S, Nörz D, Lütgehetmann M. Evaluation of a quantitative
399 RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high
400 throughput system. Euro Surveill 2020; 25(9): 2000152.
- 401 30. Okamaoto K, Shirato K, Nao N, et al. An assessment of real-time RT-PCR kits for
402 SARS-CoV-2 detection. Jpn J Infect Dis 2020. DOI:
403 <https://doi.org/10.7883/yoken.JJID.2020.108>
- 404 31. Yan C, Cui J, Huang L, et al. Rapid and visual detection of 2019 novel coronavirus
405 (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay. Clin
406 Microbiol Infect 2020; 26(6): 773-9.

407

408

409 **Figure Legends**

410 **Figure 1. Ct value and detection time for each molecular diagnostic test of saliva**

411 **specimens.** Cycle threshold (Ct) value for each RT-qPCR primer set and detection time by

412 reverse-transcription loop mediated isothermal amplification (RT-LAMP). Horizontal lines
413 indicate the mean Ct value or detection time. *p* value was calculated using the Student's t-test.

414

415 **Figure 2. Relation of RT-qPCR, RT-LAMP, and rapid antigen test of saliva specimens.**

416 (A) Relation between detection time of reverse-transcription loop mediated isothermal
417 amplification (RT-LAMP) and Ct value of target 2 (SARS-CoV-2 envelope gene) in cobas
418 SARS-CoV-2 test. The blue slope line represents the fitted regression curve. The gray shadow
419 indicates a 95% confidence interval around the regression curve. (B) Distribution of Ct value
420 of target 2 in cobas SARS-CoV-2 test of saliva with positive and negative results. Horizontal
421 lines indicate the mean Ct value. *p* value was calculated using the Student's t-test.

422

423

424 **Table 1. Summary of results of molecular diagnostic tests and rapid antigen test for**
 425 **COVID-19 on self-collected saliva samples.**

| | Total n = 103 | Time from onset to collection | | Asymptomatic n = 15 | p value ^a |
|--------------------------------|--------------------------|-------------------------------------|------------------------------------|--------------------------|----------------------|
| | | Early phase (≤ 9 days) n = 61 | Late phase (9 days <) n = 27 | | |
| LDT RT-qPCR^b | 84 (81.6) [72.7-88.5] | 57 (93.4) [84.1-98.2] | 17 (63.0) [42.4-80.6] | 10 (66.7) [38.4-88.2] | < 0.001 |
| N-1 set | 76 (73.8) [64.2-82.0] | 54 (88.5) [77.8-95.2] | 14 (51.9) [31.9-71.3] | 8 (53.3) [26.6-78.7] | |
| N-2 set | 83 (80.6) [71.6-87.7] | 57 (93.4) [84.1-98.2] | 16 (59.3) [38.8-77.6] | 10 (66.7) [38.4-88.2] | |
| cobas SARS-CoV2 test | 83 (80.6) [71.6-87.7] | 56 (91.8) [81.9-97.3] | 18 (66.7) [46.0-83.5] | 9 (60.0) [32.3-83.7] | < 0.001 |
| Target 1 | 76 (73.8) [64.2-82.0] | 54 (88.5) [77.8-95.2] | 14 (51.9) [31.9-71.3] | 8 (53.3) [26.6-78.7] | |
| Target 2 | 83 (80.6) [64.2-82.0] | 56 (91.8) [81.9-97.3] | 18 (66.7) [46.0-83.5] | 9 (60.0) [32.3-83.7] | |
| Direct RT-qPCR | | | | | |

| | | | | | |
|-----------------------------|--------------------------|--------------------------|--------------------------|--------------------------|---------|
| Method A^c | 79 (76.7) [67.3-84.5] | 53 (86.9) [75.8-94.2] | 16 (59.3) [38.8-77.6] | 10 (66.7) [38.4-88.2] | 0.012 |
| Method B^d | 81 (78.6) [69.5-86.1] | 55 (90.2) [79.8-96.3] | 17 (63.0) [42.4-80.6] | 9 (60.0) [32.3-83.7] | 0.003 |
| N-1 set | 80 (77.7) [68.4-85.3] | 54 (88.5) [77.8-95.3] | 17 (63.0) [42.4-80.6] | 9 (60.0) [32.3-83.7] | |
| N-2 set | 63 (61.2) [51.1-70.6] | 48 (78.7) [66.3-88.1] | 8 (29.6) [13.8-50.2] | 7 (46.7) [21.3-73.4] | |
| Method C^e | 52 (50.5) [40.5-60.5] | 40 (65.6) [52.3-77.3] | 6 (22.2) [8.6-42.3] | 6 (40.0) [16.3-67.7] | < 0.001 |
| N-1 set | 15 (14.6) [8.4-22.9] | 9 (14.8) [7.0-26.1] | 2 (7.4) [1.0-24.3] | 4 (26.7) [7.8-55.1] | |
| N-2 set | 51 (49.5) [39.5-59.5] | 40 (65.6) [52.3-77.3] | 6 (22.2) [8.6-42.3] | 5 (33.3) [11.8-61.6] | |
| RT-LAMP | 73 (70.9) [61.1-79.4] | 52 (85.2) [73.8-93.0] | 12 (44.4) [25.5-64.7] | 9 (60.0) [32.3-83.7] | < 0.001 |
| Rapid antigen test | 12 (11.7) [6.2-19.5] | 8 (13.1) [5.8-24.2] | 2 (7.4) [1.0-24.3] | 2 (13.3) [1.7-40.5] | 0.728 |

426 Data are presented as n (%) [95% confidence interval], unless otherwise specified.

427 ^a*p* value was calculated using Kruskal-Wallis test.

428 ^bLDT, Laboratory-developed test.

429 ^cMethod A, SARS-CoV-2 Direct Detection RT-qPCR Kit (Takara Bio Inc. Kusatsu, Japan).

430 ^dMethod B, Ampdirect™ 2019 Novel Coronavirus Detection Kit (Shimadzu Corporation,

431 Kyoto, Japan).

432 ^eMethod C, SARS-CoV-2 Detection Kit (Toyobo, Osaka, Japan).

433

434 **Table 2. Effect of clinical background against the presence of viral RNA in saliva of 103**
 435 **asymptomatic and symptomatic patients**

| | Presence of viral RNA in saliva | | | <i>p</i> value ^a |
|-------------------------|---------------------------------|--------------------|--------------------|-----------------------------|
| | Total n = 103 | Positive n = 84 | Negative n = 19 | |
| Age (years) | 48 [36–63] | 47 [39-67] | 44 [38-55] | 0.195 |
| Sex | | | | 0.035 |
| Male | 66 (64.1) | 58 (69.0) | 8 (42.1) | - |
| Female | 37 (35.9) | 26 (31.0) | 11 (57.9) | - |
| Disease activity | | | | 0.146 |
| Asymptomatic | 15 (14.6) | 10 (11.9) | 5 (26.3) | - |
| Symptomatic | 88 (85.4) | 74 (88.1) | 14 (73.7) | - |

436 Data are presented as n (%) or median [interquartile range], unless otherwise specified.

437 ^a*p* value was calculated using Wilcoxon rank-sum test for continuous variable, and χ^2 test or

438 Fisher’s exact test for categorical variables.

439

440 **Table 3. Effect of clinical background against the presence of viral RNA in saliva of 88**
 441 **symptomatic patients**

| | Presence of viral RNA in | | | <i>p</i> value ^a |
|--------------------------|--------------------------------|--------------------|--------------------|-----------------------------|
| | Symptomatic patients n = 88 | saliva | | |
| | | Positive n = 74 | Negative n = 14 | |
| Age (years-old) | 46 [38-62] | 46 [38-60] | 44 [37-53] | 0.344 |
| Sex (male) | | | | 0.011 |
| Male | 59 (67.0) | 54 (73.0) | 5 (35.7) | - |
| Female | 29 (33.0) | 20 (27.0) | 9 (64.3) | - |
| Disease severity | | | | 0.064 |
| Mild | 72 (81.8) | 58 (78.4) | 14 (100) | - |
| Severe | 16 (18.2) | 16 (21.6) | - | - |
| Clinical symptoms | | | | |
| Fever | 73 (83.0) | 62 (83.8) | 11 (78.6) | 0.700 |
| Cough | 45 (51.1) | 41 (55.4) | 4 (28.6) | 0.084 |
| Malaise | 30 (34.1) | 25 (33.8) | 5 (35.7) | 1.000 |
| Headache | 25 (28.4) | 22 (29.7) | 3 (21.4) | 0.749 |

| | | | | |
|--|-----------|-----------|----------|-------|
| Diarrhea | 20 (22.7) | 15 (20.3) | 5 (35.7) | 0.294 |
| Sore throat | 19 (21.6) | 15 (20.3) | 4 (28.6) | 0.491 |
| Tachypnea | 13 (14.8) | 13 (17.6) | - | 0.117 |
| Dyspnea | 8 (9.1) | 8 (10.8) | - | 0.346 |
| Hypoxemia (SpO₂ < 93 %) | 10 (11.4) | 10 (13.5) | - | 0.353 |

442 Data are presented as n (%) or median [interquartile range], unless otherwise specified.

443 ^a*p* value was calculated using Wilcoxon rank-sum test for continuous variable, and χ^2 test or

444 Fisher's exact test for categorical variables.

Figure 1




Figure 2

